Reviewed Mar 2026 | PubMed sources
Active Market
This comparison can feed directly into US-first legal, provider, and cost workflows.

Semaglutide vs Tirzepatide: Head-to-Head Comparison

Both are FDA-approved for type 2 diabetes and obesity. Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist, while tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist. Clinical trials show tirzepatide achieves greater weight loss on average, but both are considered breakthrough therapies.

Approved Comparison Routing

Approved options in this comparison

A
Semaglutide

Semaglutide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Ozempic, Wegovy, Rybelsus.

A
Tirzepatide

Tirzepatide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Mounjaro, Zepbound.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Need help choosing between prescribing paths?

One or more options in this comparison are currently modeled on this site as approved treatment paths. Use the provider matcher to narrow the best next step based on your budget, insurance, and timeline.

Find a provider

Semaglutide Next Steps

US-first money path

Tirzepatide Next Steps

US-first money path

Side-by-Side Comparison

DimensionSemaglutideTirzepatide
Evidence LevelPhase III (STEP trials); extensive real-world dataPhase III (SURMOUNT/SURPASS trials); newer but robust
FDA StatusFDA-approved for T2D (Ozempic) and obesity (Wegovy)FDA-approved for T2D (Mounjaro) and obesity (Zepbound)
MechanismGLP-1 receptor agonistDual GIP and GLP-1 receptor agonist
Weight Loss Efficacy~15-17% body weight loss in trials~20-22.5% body weight loss in trials
Side EffectsNausea, vomiting, diarrhea, pancreatitis riskNausea, vomiting, diarrhea (similar GI profile)
DosingWeekly subcutaneous injectionWeekly subcutaneous injection
Cost~$1,000-1,300/month (brand)~$1,000-1,200/month (brand)
Evidence Level
Semaglutide
Phase III (STEP trials); extensive real-world data
Tirzepatide
Phase III (SURMOUNT/SURPASS trials); newer but robust
FDA Status
Semaglutide
FDA-approved for T2D (Ozempic) and obesity (Wegovy)
Tirzepatide
FDA-approved for T2D (Mounjaro) and obesity (Zepbound)
Mechanism
Semaglutide
GLP-1 receptor agonist
Tirzepatide
Dual GIP and GLP-1 receptor agonist
Weight Loss Efficacy
Semaglutide
~15-17% body weight loss in trials
Tirzepatide
~20-22.5% body weight loss in trials
Side Effects
Semaglutide
Nausea, vomiting, diarrhea, pancreatitis risk
Tirzepatide
Nausea, vomiting, diarrhea (similar GI profile)
Dosing
Semaglutide
Weekly subcutaneous injection
Tirzepatide
Weekly subcutaneous injection
Cost
Semaglutide
~$1,000-1,300/month (brand)
Tirzepatide
~$1,000-1,200/month (brand)

Peptide Overviews

Semaglutide

AFDA Approved

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.

Weight LossFDA Approved
View full Semaglutide profile →

Tirzepatide

AFDA Approved

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.

Weight LossFDA Approved
View full Tirzepatide profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Semaglutide vs Tirzepatide: FAQ